以色列 - 希伯来文 - Ministry of Health

tzamal medical ltd - אחות - לפי הוראות יצרן

以色列 - 希伯来文 - Ministry of Health

tzamal medical ltd - רופא - ניתוחי עמוד שידרה

以色列 - 希伯来文 - Ministry of Health

trimaco medical division ltd. - רופא - משתלים אורטופדיים, מערכות אורטופדיות,ומכשור אורטופדי ולניתוחי עמוד שידרה

以色列 - 希伯来文 - Ministry of Health

trimaco medical division ltd. - רופא - משתלים ומכשור לניתוחים אורטופדיים-בעיקר פרוצדורות של עמוד שידרה ושלד מיכשור כגון: פלטות,אומים,מוטות,ברגים

以色列 - 希伯来文 - Ministry of Health

amgen europe b.v. - romiplostim - אבקה להכנת תמיסה לזריקה - romiplostim 250 mcg/vial - romiplostim - romiplostim - nplate is indicated for the treatment of thrombocytopaenia in adult patients with chronic immune (idiopathic) thrombocytopaenic purpura (itp)- who are non-splenectomised and have had an inadequate response, or are intolerant, to both corticosteroids and immunoglobulins;-who are splenectomised and have had an inadequate response to splenectomy

以色列 - 希伯来文 - Ministry of Health

amgen europe b.v. - cinacalcet hydrochloride 30 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

以色列 - 希伯来文 - Ministry of Health

amgen europe b.v. - cinacalcet hydrochloride 60 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

以色列 - 希伯来文 - Ministry of Health

amgen europe b.v. - cinacalcet hydrochloride 90 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

以色列 - 希伯来文 - Ministry of Health

amgen europe b.v. - pegfilgrastim - תמיסה להזרקה - pegfilgrastim 10 mg/ml ml - pegfilgrastim - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. ( with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

以色列 - 希伯来文 - Ministry of Health

amgen europe b.v. - denosumab - תמיסה להזרקה - denosumab 60 mg / 1 ml - denosumab - denosumab - treatment of osteoporosis in postmenopausal women at incresed risk of fractures. prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. in men with prostate cancer receiving hormone ablation, prolia significantly reduces the risk of vertebral fractures.